BioCentury
ARTICLE | Company News

Prev AbR LLC, Synthetic Biologics deal

November 19, 2012 8:00 AM UTC

Synthetic will acquire from Prev products targeting beta-lactamase to prevent Clostridium difficile infection. Prev received $100,000 up front, and will receive $135,000 in cash and 625,000 Synthetic ...